

John H Lynch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4421661/publications.pdf>

Version: 2024-02-01

42
papers

618
citations

567281

15
h-index

610901

24
g-index

42
all docs

42
docs citations

42
times ranked

787
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal Balloons. <i>International Journal of Particle Therapy</i> , 2022, 9, 28-41.	1.8	0
2	Retzius-sparing Robot-assisted Radical Prostatectomy Leads to Durable Improvement in Urinary Function and Quality of Life Versus Standard Robot-assisted Radical Prostatectomy Without Compromise on Oncologic Efficacy: Single-surgeon Series and Step-by-step Guide. <i>European Urology</i> , 2021, 79, 839-857.	1.9	54
3	Sex and Racial Disparities in the Treatment and Outcomes of Muscle-invasive Bladder Cancer. <i>Urology</i> , 2021, 151, 154-162.	1.0	17
4	Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 551491.	2.8	0
5	Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP). <i>Frontiers in Oncology</i> , 2020, 10, 555.	2.8	10
6	Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15). <i>Frontiers in Oncology</i> , 2020, 10, 1060.	2.8	7
7	The Balance between Open and Robotic Training among Graduating Urology Residents—Does Surgical Technique Need Monitoring?. <i>Journal of Urology</i> , 2020, 203, 996-1002.	0.4	9
8	Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer. <i>Investigative and Clinical Urology</i> , 2020, 61, 390.	2.0	6
9	Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy. <i>Scientific Reports</i> , 2019, 9, 15272.	3.3	3
10	The Impact of Institutional Factors on Physician Burnout: A National Study of Urology Trainees. <i>Urology</i> , 2019, 131, 27-35.	1.0	39
11	Resident burnout in USA and European urology residents: an international concern. <i>BJU International</i> , 2019, 124, 349-356.	2.5	58
12	Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT). <i>Frontiers in Oncology</i> , 2019, 9, 1528.	2.8	5
13	Discovery of Metabolic Biomarkers Predicting Radiation Therapy Late Effects in Prostate Cancer Patients. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1164, 141-150.	1.6	4
14	Self-reported burden in patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 51-51.	1.6	0
15	Patient-reported anxiety with localized prostate cancer treated with stereotactic body radiation therapy (SBRT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 52-52.	1.6	1
16	Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer. <i>Acta Oncol3gica</i> , 2017, 56, 1136-1138.	1.8	13
17	Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity. <i>Frontiers in Oncology</i> , 2017, 7, 5.	2.8	17
18	Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?. <i>Frontiers in Oncology</i> , 2017, 7, 157.	2.8	15

#	ARTICLE	IF	CITATIONS
19	Prostate specific antigen five years following stereotactic body radiation therapy (SBRT) for low and intermediate risk prostate cancer: An ablative procedure?. <i>Journal of Clinical Oncology</i> , 2017, 35, 123-123.	1.6	0
20	Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience. <i>Frontiers in Oncology</i> , 2016, 6, 114.	2.8	28
21	Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction. <i>Frontiers in Oncology</i> , 2016, 6, 122.	2.8	20
22	Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design. <i>Frontiers in Oncology</i> , 2016, 6, 167.	2.8	15
23	Adoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice. <i>Urology Practice</i> , 2015, 2, 190-198.	0.5	5
24	Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 151.	2.8	5
25	Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging. <i>Frontiers in Oncology</i> , 2015, 5, 194.	2.8	11
26	Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?. <i>Frontiers in Oncology</i> , 2015, 5, 77.	2.8	14
27	Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. <i>Radiation Oncology</i> , 2015, 10, 44.	2.7	22
28	Proctitis following stereotactic body radiation therapy for prostate cancer. <i>Radiation Oncology</i> , 2014, 9, 277.	2.7	26
29	Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥ 50 cm ³). <i>Radiation Oncology</i> , 2014, 9, 241.	2.7	41
30	Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 290.	2.8	13
31	Late Urinary Symptom Flare After Prostate Stereotactic Body Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 3451-3452.	1.6	8
32	Clinical Characteristics and Management of Late Urinary Symptom Flare Following Stereotactic Body Radiation Therapy for Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 122.	2.8	28
33	Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 303-308.	1.6	22
34	The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. <i>Oncotarget</i> , 2014, 5, 10678-10691.	1.8	36
35	Bother following stereotactic body radiation therapy for clinically localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 195-195.	1.6	0
36	Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 293.	2.8	20

#	ARTICLE	IF	CITATIONS
37	Stereotactic body radiation therapy (SBRT) following procedures for benign prostatic hyperplasia (BPH): A report on early toxicity.. Journal of Clinical Oncology, 2013, 31, 165-165.	1.6	0
38	Hydroxyproline as a Marker for Following Patients with Metastatic Prostate Cancer. Journal of Urology, 1988, 139, 66-68.	0.4	7
39	Renal Cell Carcinoma. Hospital Practice (1995), 1987, 22, 59-67.	1.0	2
40	Thrombosis of the Inferior Vena Cava by Seminoma. Journal of Urology, 1987, 137, 303-305.	0.4	28
41	Case Report: Complete Response of Metastatic Transitional Cell Carcinoma of the Bladder with Chemotherapy Alone. Journal of Urology, 1984, 131, 340-342.	0.4	0
42	Use of Ephedrine in Post-Lymphadenectomy Ejaculatory Failure: A Case Report. Journal of Urology, 1983, 129, 379-379.	0.4	9